BioVie Highlights Encouraging NE3107 Data In Parkinson's, Alzheimer's Trials

BioVie Highlights Encouraging NE3107 Data In Parkinson's, Alzheimer's Trials
  • BioVie Inc BIVI announced results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD).
  • Parkinson's patients treated with the combination of NE3107 and levodopa improved their UPDRS Part 3 (motor) score, which is 3+ points superior to those treated with levodopa alone.
  • Patients younger than 70 years old treated with NE3107 and levodopa experienced improvements that are roughly 6 points better than levodopa-treated alone. Patients younger than 70 years old represented roughly one-half of the study participants.
  • Related: This Small Biotech Company Touts Promising Data For Alzheimer's Candidate.
  • After 28 days of treatment, 63.6% of patients treated with levodopa alone experienced >30% improvement from Day 0 at the two-hour mark compared to 80% for NE3107+levodopa-treated patients and 88.9% of NE3107+levodopa patients under 70 years old. 
  • There were no drug-related adverse events.
  • Full details from this trial will be presented at the upcoming Conference next year.
  • The company also shared additional data from Alzheimer's trial, demonstrating enhanced cognition after three months of treatment with NE3107 compared to baseline.
  • Patients showed improvement in daily function and reduced inflammation, with 18 of 22 patients with abnormal baseline scans showing improvement in one or more brain regions.
  • Price Action: BIVI shares are up 16.10% at $6.05 during the premarket session on the last check Tuesday.

Posted In: Briefswhy it's movingBiotechNewsHealth CarePre-Market OutlookMoversTrading IdeasGeneral